Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,597,456 shares of the specialty pharmaceutical company’s stock after selling 155,426 shares during the period. Pacer Advisors Inc. owned 2.89% of Supernus Pharmaceuticals worth $57,764,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares during the period. Assetmark Inc. raised its stake in Supernus Pharmaceuticals by 2.8% during the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock valued at $1,043,000 after acquiring an additional 908 shares during the last quarter. Finally, KBC Group NV lifted its position in Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares during the period.

Analyst Ratings Changes

SUPN has been the topic of a number of recent research reports. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 price objective on the stock. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $39.41 on Tuesday. The company has a market cap of $2.18 billion, a P/E ratio of 36.83 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.69. The business has a fifty day moving average of $36.91 and a two-hundred day moving average of $34.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter last year, the business earned ($0.29) earnings per share. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.